Literature DB >> 3312034

[Clinical and bacteriologic effectiveness of ceftazidime in infections with gram-positive pathogens].

R Tolxdorff-Neutzling1, G Klages, H Danner.   

Abstract

From June 1984 to March 1985 an open, multicenter study was carried out to evaluate the efficacy and safety of ceftazidime in the empirical treatment of severe nosocomial infections. 3799 patients treated in 513 clinical care units were included and 3477 were evaluable. The majority was older than 60 years; most patients showed severe underlying diseases and were in a critical condition. The clinical and bacteriological results with various monoinfections due to gram-positive bacteria are presented. Staphylococcus aureus, Streptococcus pneumoniae and other streptococci were the most frequently isolated organisms. 600 patients with infections due to staphylococci were evaluated separately. The clinical success rate with ceftazidime in S. aureus monoinfections was 90.9%, and the bacteriological success rate was 74.9%.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3312034     DOI: 10.1007/BF01645870

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  5 in total

1.  A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients.

Authors:  B de Pauw; K Williams; J de Neeff; T Bothof; T de Witte; R Holdrinet; C Haanen
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

2.  Comparative multiple-dose pharmacokinetics of cefotaxime, moxalactam, and ceftazidime.

Authors:  R Lüthy; J Blaser; A Bonetti; H Simmen; R Wise; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1981-11       Impact factor: 5.191

3.  Treatment of skin, skin structure, bone, and joint infections with ceftazidime.

Authors:  L O Gentry
Journal:  Am J Med       Date:  1985-08-09       Impact factor: 4.965

4.  Ceftazidime--a new extended-spectrum cephalosporin.

Authors:  D I Gozzard; A M Geddes; I D Farrell; S J Eykyn; I Phillips; R Wise; R M Brown
Journal:  Lancet       Date:  1982-05-22       Impact factor: 79.321

5.  The in-vitro activity of ceftazidime against clinically important pathogens.

Authors:  H Knothe; G A Dette
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.